Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (not Quoin Pharmaceuticals, Ltd.) on January 28, 2019. The filing incorporates by reference a press release dated January 28, 2019, announcing the completion of manufacturing for clinical-grade FasL (Fas Ligand).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate development milestone rather than financial performance.
Material Changes
The primary material change reported is the successful completion of manufacturing for clinical-grade FasL. This milestone is expected to enable the company to expedite its U.S. clinical programs into multiple studies.
Guidance, Outlook, and Risks
Management commentary indicates that the manufacturing completion will accelerate clinical trial timelines in the United States. The filing incorporates "Forward Looking Statements" from the attached press release, though specific quantitative guidance or detailed risk factors are not enumerated in the provided text.
Investor Verification Checklist
- Verify the specific timeline for the initiation of the expedited U.S. clinical studies.
- Confirm the regulatory status of the clinical-grade FasL with relevant health authorities.
- Review the full text of the attached press release (Exhibit 99.1) for detailed forward-looking statements and associated risks.
- Check subsequent filings for updates on the progress of the clinical programs mentioned.